Compare NNNN & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNNN | GEVO |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.2M | 340.8M |
| IPO Year | 2023 | 2010 |
| Metric | NNNN | GEVO |
|---|---|---|
| Price | $7.90 | $1.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.58 |
| AVG Volume (30 Days) | 99.2K | ★ 2.9M |
| Earning Date | 04-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $711,000.00 |
| Revenue This Year | N/A | $19.44 |
| Revenue Next Year | N/A | $5.59 |
| P/E Ratio | $446.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.61 | $1.37 |
| 52 Week High | $51.33 | $2.97 |
| Indicator | NNNN | GEVO |
|---|---|---|
| Relative Strength Index (RSI) | 37.25 | 48.38 |
| Support Level | N/A | $1.40 |
| Resistance Level | $13.01 | $1.57 |
| Average True Range (ATR) | 1.67 | 0.08 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 18.56 | 46.67 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.